Surface Oncology, Merck to Study SRF617, Keytruda Combination
May 20 2020 - 8:05AM
Dow Jones News
By Colin Kellaher
Surface Oncology Inc. on Wednesday said it would collaborate
with Merck & Co. to study its SRF617 investigational antibody
therapy in combination with Merck's Keytruda cancer drug in
patients with solid tumors.
Surface, a Cambridge, Mass., clinical-stage immuno-oncology
company, said the companies will study the combination as a
component of a first-in-human phase 1/1b study of SRF617.
Surface said the study would focus on patients with gastric
cancer and those who have developed resistance to checkpoint
inhibition, both areas of high unmet need.
Shares of Surface, which closed Tuesday at $2.66, surged 42% in
premarket trading Wednesday.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
May 20, 2020 07:50 ET (11:50 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2023 to Apr 2024
